ARA 290 (cibinetide) is a non-haematopoietic peptide designed from the structure of erythropoietin that interacts selectively with the innate repair receptor mediating tissue protection.
fact added identity: CAS registry number 1208243-50-8. · 2026-09-27 04:00 · somebody
fact added summary: ARA 290 (cibinetide) is a non-haematopoietic peptide designed from the structure of erythropoietin that interacts select · 2026-09-27 04:00 · somebody
fact added history: In a phase 2 study in type 2 diabetes, 28 days of daily subcutaneous ARA 290 was followed by improvements in HbA1c, lipi · 2026-09-27 04:00 · somebody
fact added history: In a small randomized pilot study of sarcoidosis with small fibre neuropathy, it improved neuropathy screening scores ov · 2026-09-27 04:00 · somebody
citation added pmid 25387363 cited as emerging: Phase 2: metabolic control and neuropathic symptoms improved in type 2 diabetes · 2026-09-27 04:00 · somebody
citation added pmid 23168581 cited as emerging: Randomized pilot in sarcoidosis-associated small fibre neuropathy (22 patients) · 2026-09-27 04:00 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.